Marinus pharmaceuticals inc.
Marinus Pharmaceuticals, Inc. (b). Address of Issuer's Principal Executive Offices: 5 Radnor Corporate Center, Suite 500. 100 Matsonford Rd. Radnor, PA 19087 . Item 2. (a) – (c) Name, Principal Business Address, and Citizenship of Persons Filing: Suvretta Capital Management, LLC – Delaware.
Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number V1.1 For complete information and to vote, visit www.ProxyVote.com Control # V12734-P90840 MARINUS PHARMACEUTICALS, INC. …Aug 10, 2023 · Marinus to host conference call on August 10, 2023, at 8:30 a.m. ET RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June ... About Marinus Pharmaceuticals Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY ® (ganaxolone) oral suspension CV, has been approved by the U.S. Food and Drug Administration for the treatment of seizures associated with ...RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the acceptance of seven abstracts for presentation at the upcoming American Epilepsy Society (AES) 2023 Annual Meeting, taking place in Orlando, Florida December 1-5, 2023.
Item 8.01. Other Events. On November 28, 2023, Marinus Pharmaceuticals, Inc. posted an updated corporate presentation on its website at www.marinuspharma.com. A copy of the corporate presentation is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Item 9.01.Marinus to host conference call today at 4:05 p.m. ET RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March …Oct 24, 2023 · RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023. The Company will host a ...
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript November 7, 2023 Marinus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.61, expectations were ...Jul 14, 2022 · RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million.
MARINUS PHARMACEUTICALS, INC. NON-QUALIFIED STOCK OPTION AGREEMENT — INCORPORATED TERMS AND CONDITIONS . 1. Grant Under Plan.. This option is granted pursuant to and is governed by the Company’s 2005 Stock Option and Incentive Plan (the “Plan”) and, unless the context otherwise requires, terms used herein without …Marinus Pharmaceuticals last issued its quarterly earnings data on November 7th, 2023. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.06. The firm had revenue of $7.34 million for the quarter, compared to analyst estimates of $6.54 million.Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is ...As pet owners, we want to keep our furry friends safe and secure. Invisible Fence Inc. has been providing pet owners with innovative solutions to keep their pets out of harm’s way for over 40 years. With their advanced technology, Invisible...
About Marinus. Marinus is committed to improving the lives of patients with seizure disorders through the development of innovative treatment options and by closely …
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the dedicated to the development of innovative therapeutics to treat orphan seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.About Marinus Pharmaceuticals. Marinus is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a neuroactive steroid GABA A receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral dose ...Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.Oct 6, 2023 · RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new employees. 31 Jul 2023 ... RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of ...18 Mar 2022 ... Marinus is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a ...RADNOR, Pa., January 05, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today ...
Chairman and Chief Executive Officer. Marinus Pharma. Nov 2022 - Present1 year. Radnor, Pennsylvania, United States.RADNOR, Pa.-- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved ZTALMY ® (ganaxolone) oral suspension for the treatment of seizures associated wit...Status epilepticus is a life-threatening condition resulting from either the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms which lead to abnormally prolonged seizures. Status epilepticus is the second most common neurological emergency in the U.S. and is associated with significant mortality ...Tracfone Wireless Inc has been a leading player in the telecommunications industry, offering innovative solutions and cutting-edge technology to its customers. With a focus on providing reliable and affordable wireless services, Tracfone ha...Nov 7, 2023 · RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the initiation of the Marinus Access Program, a global managed access program for ZTALMY ® (ganaxolone) oral suspension CV. Nov 7, 2023 · RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the initiation of the Marinus Access Program, a global managed access program for ZTALMY ® (ganaxolone) oral suspension CV.
RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has resumed screening and recruitment for the Phase 3 RAISE (Randomized Therapy in Status Epilepticus) trial in refractory status ...
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.united states. securities and exchange commission. washington, d.c. 20549 form 8-k. current report. pursuant to section 13 or 15(d) of the securities exchange act of 1934united states. securities and exchange commission. washington, d.c. 20549 form 8-k. current report. pursuant to section 13 or 15(d) of the securities exchange act of 1934Registrant’s telephone number, including area code: (484) 801-4670 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ ☐Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.MARINUS PHARMACEUTICALS, INC. INDUCEMENT AWARD. NONQUALIFIED STOCK OPTION AGREEMENT. Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.001 (the “Stock”), to the recipient (the …
Feb 13, 2023 · RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023. The Company will host a conference ...
RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the speakers for its upcoming Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Time in New York.
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby grants restricted Stock Units (the “RSUs”) representing the right to receive shares of its common stock, par value $0.001 (the “Stock”), to the recipient (the “Grantee”) set forth on the Schedule to Restricted Stock Unit Agreement attached hereto (the “Schedule”), …(2) Represents shares of common stock, $0.001 par value per share (“Common Stock”) of Marinus Pharmaceuticals, Inc. (the “Registrant”) reserved for issuance pursuant to stock option awards (“Options”) outstanding under the Registrant’s 2014 Equity Incentive Plan, as amended (the “2014 Plan”), as of the date of this …About Marinus Pharmaceuticals Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY ® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder ...Dec 1, 2023 · Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus Pharmaceuticals stock opened at $7.50 on Tuesday. The company has a debt-to-equity ratio of 1.79, a current ratio of 6.38 and a quick ratio of 6.29. The …RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the speakers for its upcoming Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern …Marinus to host conference call today at 4:05 p.m. ET RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March …Company Description: Marinus Pharmaceuticals is ready to put an end to epileptic seizures. The biopharmaceutical company is developing a drug candidate, ganaxolone, to be used as an add-on therapy for the treatment of partial onset seizures in people with epilepsy. Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, offering a new mechanism of action with demonstrated safety and convenient dosing for patients affected by epilepsy and CNS disorders.There are some variant perceptions on Marinus Pharmaceuticals, with the most bullish analyst valuing it at US$50.00 and the most bearish at US$17.00 per share. We would probably assign less value ...Nov 29, 2023 · 9 brokers have issued 12-month price targets for Marinus Pharmaceuticals' shares. Their MRNS share price targets range from $9.00 to $28.00. On average, they predict the company's stock price to reach $20.72 in the next year. This suggests a possible upside of 207.0% from the stock's current price.
Marinus to host conference call on August 10, 2023, at 8:30 a.m. ET RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June ...Mar 6, 2023 · RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 1 new employee. The Compensation Committee of the Board of Directors of Marinus approved the grant of non ... RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the acceptance of seven abstracts for presentation at the upcoming American Epilepsy Society (AES) 2023 Annual Meeting, taking place in Orlando, Florida December 1-5, 2023.Instagram:https://instagram. vtak stockverizon networthpresentation skills coursespolished.com Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. h i l sregional bank etf 3x Marinus Pharmaceuticals, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 16,000,000 shares of its common stock, par value $0.001 per share (the “Shares”). affordable dental insurance arkansas RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new employees.About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a ...Dec 8, 2020 · Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.